GlucoTrack (NASDAQ:GCTK) Trading Down 0.3% – What’s Next?

GlucoTrack, Inc. (NASDAQ:GCTK)’s stock price fell 0.3% during trading on Thursday . The stock traded as low as $6.31 and last traded at $6.43. 27,702 shares changed hands during mid-day trading, a decline of 72% from the average session volume of 100,413 shares. The stock had previously closed at $6.45.

Analyst Ratings Changes

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of GlucoTrack in a research note on Wednesday, October 8th. One research analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the stock presently has a consensus rating of “Sell”.

GlucoTrack Trading Down 0.3%

The firm has a 50-day moving average price of $6.32 and a 200-day moving average price of $7.12. The company has a current ratio of 3.27, a quick ratio of 3.27 and a debt-to-equity ratio of 0.03. The stock has a market capitalization of $5.79 million, a PE ratio of -0.01 and a beta of 0.22.

GlucoTrack (NASDAQ:GCTK) last posted its quarterly earnings data on Thursday, August 14th. The company reported ($9.62) earnings per share (EPS) for the quarter.

Institutional Investors Weigh In On GlucoTrack

A hedge fund recently raised its stake in GlucoTrack stock. Bank of America Corp DE lifted its stake in shares of GlucoTrack, Inc. (NASDAQ:GCTK) by 102,125.0% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 4,089 shares of the company’s stock after purchasing an additional 4,085 shares during the period. Bank of America Corp DE owned 0.85% of GlucoTrack worth $25,000 at the end of the most recent quarter. Institutional investors own 10.92% of the company’s stock.

About GlucoTrack

GlucoTrack, Inc, a medical device company, focused on the design, development, and commercialization of novel technologies for people with diabetes in the United States. It develops GlucoTrack, a noninvasive glucose monitoring device that helps people with diabetes and pre-diabetics to obtain blood glucose level readings without the pain.